CA
XENE icon

Continuum Advisory’s Xenon Pharmaceuticals XENE Stock Holding History

Continuum Advisory’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27
Closed -$906 – 1601
2025
Q1 		$906 Hold
27
– – ﹤0.01% 1520
2024
Q4 		$1.06K Hold
27
– – ﹤0.01% 1603
2024
Q3 		$1.13K Buy
27
+12
+80% +$484 ﹤0.01% 1597
2024
Q2 		$585 Hold
15
– – ﹤0.01% 1572
2024
Q1 		$637 Buy
+15
New +$690 ﹤0.01% 1562

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Continuum Advisory's XENE Position: Q2 2025 in Review

Continuum Advisory sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 27 shares — an estimated $906 sold.

Continuum Advisory first reported a position in XENE in Q1 2024 and held it in 5 quarters. The position peaked at $1.13K in Q3 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Continuum Advisory reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 27 Xenon Pharmaceuticals shares in Q2 2025, an estimated $906.
  • Continuum Advisory first reported a position in Xenon Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Xenon Pharmaceuticals position peaked at $1.13K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.